FDA clears genetically engineered TIL therapy for solid tumour trials
Drug Discovery World
SEPTEMBER 3, 2024
Grit Biotechnology has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) for its genetically engineered tumour-infiltrating lymphocyte (TIL) product GT201. GT201 is designed to boost T cell survival and function by expressing a vital membrane-bound cytokine complex.
Let's personalize your content